DRG Epidemiology’s coverage of acute respiratory distress syndrome (ARDS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of ARDS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

DRG Epidemiology’s ARDS forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ARDS over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following ARDS subpopulations:

  • Diagnosed incident events.
  • Diagnosed incident events by severity.
  • Diagnosed incidents events by type of pulmonary injury.
  • Diagnosed incident events of sepsis-related versus non-sepsis-related ARDS.

Note: Coverage may vary by country.

Table of contents

  • Acute Respiratory Distress Syndrome - Epidemiology - Mature Markets Data
    • Introduction
      • Diagnosed Incident Events of Acute Respiratory Distress Syndrome per 100,000 per Year Among People of All Ages in 2018 and 2038
      • Relative Sizes of the Factors Contributing to the Trend in Diagnosed Incident Events of Acute Respiratory Distress Syndrome over the Next 20 Years
      • Analysis of Diagnosed Incident Events of Acute Respiratory Distress Syndrome in the Countries Under Study in 2018 by Severity
      • Analysis of Diagnosed Incident Events of Acute Respiratory Distress Syndrome in the Countries Under Study in 2018 by Type of Pulmonary Injury
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Events of Acute Respiratory Distress Syndrome
      • Diagnosed Incident Events by Severity
      • Diagnosed Incident Cases by Type of Pulmonary Injury
      • Diagnosed Incident Cases of Acute Respiratory Distress Syndrome: Sepsis-Related vs. Non-Sepsis-Related
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Acute Respiratory Distress Syndrome
        • Studies Excluded from the Analysis of Acute Respiratory Distress Syndrome
      • Risk/Protective Factors
        • Risk/Protective Factors for Acute Respiratory Distress Syndrome
      • Bibliography
      • Glossary

Author(s): Ravdeep Kaur, M.P.H.; Alison Isherwood, M.Sc., M.Res., Ph.D.

Ravdeep Kaur, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. She holds a master’s degree in public health from the School of Public Health at the Post-Graduate Institute of Medical Education and Research and a bachelor’s degree in dental surgery from Rajiv Gandhi University of Health Sciences in India. Prior to joining DRG, she was a consultant for the Reproductive, Maternal, Child, and Adolescent Health Program, funded by the U.S. Agency for International Development.

Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.


Related Reports

Biosimilars - Market Events And Forecast - Respiratory

In 2019, sales of branded biologics in respiratory indications reached nearly $1.6 billion in the major pharmaceutical markets under study (United States,

View Details